Company / EPS (Diluted)
Kiniksa Pharmaceuticals International, plc EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.20
FY2025
5-year range
-$2.99 / $2.60
FY2021-FY2025
Trend
-92.3%
vs FY2024
Sector context
#41 of 204
Health Care
What the data says
Kiniksa Pharmaceuticals International, plc's eps (diluted) of $0.20 is higher than 80% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 7 years, ranging from $-2.99 in FY2021 to $2.60 in FY2024.
Based on SEC 10-K filings.
0.20 in FY2025. Top quartile in the Health Care sector.
Improved from $-2.30 to $0.20 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 204This company $0.20 Sector average -$0.98
▼
+120.4% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 92.3% year-over-year.
- Ranks #41 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2024.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.20 | -92.3% |
| FY2024 | $2.60 | +213.0% |
| FY2023 | -$2.30 | +11.9% |
| FY2022 | -$2.61 | +12.7% |
| FY2021 | -$2.99 | -14.6% |
| FY2020 | -$2.61 | +12.7% |
| FY2019 | -$2.99 | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026